1st Annual European Congress on Immunotherapies in Cancer
23-24 September 2016
W Barcelona, Barcelona, Spain

Register by 15 August 2016 and save €75 off the price of registration. Enter code ECIC16TF.

Nurses use code ECIC16TFN before 15 August 2016 to Register Now and Save €50.

For more information and registration, visit us at gotoper.com/europe

Co-Chair
Ramon Perez-Soler, MD
Chairman, Department of Medical Oncology
Mount Sinai Medical Center
Professor of Medicine and Oncology
University of Miami School of Medicine
Boca Raton, Florida, USA

Program Chair
Antoni Ribas, MD, PhD
Professor of Medicine
Department of Surgical Oncology and Molecular Pharmacology
David Geffen School of Medicine at the University of California, Los Angeles
Los Angeles, California, USA

1st Annual European Congress on Immunotherapies in Cancer™
23-24 September 2016
W Barcelona, Barcelona, Spain

Register now and save!
Register by 15 August 2016 and save €75 off the price of registration. Enter code ECIC16M2.

Nurses use code ECIC16HN before 15 August 2016 to Register Now and Save €50.

For more information and registration, visit us at gotoper.com/europe

Physicians’ Education Resource®, LLC is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 1st Annual European Congress on Immunotherapies in Cancer™ is designated for a maximum of 8 hours of European external CME credits. Each medical specialist should claim credit appropriate for the number of hours spent at the event. A cancellation fee of 25% will be assessed on refunds requested prior to 8 September 2016. No refunds will be made after 8 September 2016.
The European Congress on Immunotherapies in Cancer™ is a 2-day comprehensive and interactive program focused exclusively on immunotherapies and their practical application to the management of advanced Lung and Head and Neck Cancer. The program will focus on science advances, recent clinical trial results that shape current and evolving uses of these approaches, proactive methods to develop and mitigate treatment-related adverse events, current and emerging testing methods, and multidisciplinary team approaches to optimize the use of immunotherapeutic strategies to treat cancers.

To register: www.eic2016.com
End Date for registration: 15 August 2016
Use code EIC16H2 before 15 August 2016 to register now and save €75!

**For physicians use only**
Nurse use code EIC16H2 before 15 August 2016 to register now and save €50!

**Overview**

The clinical development of immunotherapies is undoubtedly one of the hottest areas in cancer research today. It is now well appreciated that the tumor microenvironment and the host immune system play important roles in cancer biology. With that understanding, modern-day immunotherapeutic approaches have emerged that do not directly target cancer cells, but harness the adaptive and innate powers of the immune system to combat cancer. These innovative strategies have been practice-changing for the management of a number of malignancies and continue to transform the way clinicians think about treating cancer. In addition to landmark data on the integration of new strategies into evolving treatment paradigms, preclinical and clinical data continue to rapidly accumulate on immunotherapy-based science.

However, the rapidity of the changes in the field and information that continues to emerge create practice and/or educational gaps for busy clinicians who strive to maintain state-of-the-art care for their patients with cancer. Educational initiatives that allow experts to place noteworthy advances in immunotherapeutic strategies in its proper clinical context will bridge these educational gaps and optimize clinical practices.

**Call for Abstracts!**

The European Congress on Immunotherapies in Cancer™ Program Chair invites you to submit your abstracts for the 1st Annual European Congress on Immunotherapies in Cancer™ to be held 23 and 24 September 2016, at the W Barcelona in Barcelona, Spain. Deadline for submission is 15 August 2016, at 11:59 AM EST (2:59 CEDT).

All poster abstracts must be submitted electronically through the congress’ online abstract submission system.

**Program Chair**

Antoni Ribas, MD, PhD
Professor of Medicine
Director, Tumor Immunology Program
Lymphoma Research Program
John Wayne Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA

Jose A Lopez-Martin, MD, PhD
Chairman, GISTCA (Grupo Español de Terapias Immunológicas, Oncológicas, y Eritropoyéticas) en Cáncer de Colección, Barri d’Oncologia, Barcelona, Spain

**Co-Chair**

Roman Perez-Soler, MD
Chairman, Department of Oncology
Memorial Sloan Kettering Cancer Center
New York, New York, USA

**Faculty**

James P. Allison, PhD
Professor and Chair, Department of Immunology
Executive Director, Immunology Institute
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA

Joaquim Bellmunt, MD, PhD
Professor, Head of the Bladder Cancer Program
Director, Institute for Immunology, Cancer Research
Vall d’Hebron University Hospital
Barcelona, Spain

George Coukos, MD
Professor and Division Head, Translational Immunology
Ludwig Institute for Cancer Research
Lausanne, Switzerland

David Haanen, MD, PhD
Head of the Division of Medical Oncology
University of British Columbia, Vancouver, British Columbia, Canada

Richard W. Vague Professor in Immunology, Assistant Professor of Medicine,Department of Pathology and Immunology, and Head of the Cancer Immunology Program
Washington University School of Medicine, St Louis, Missouri, USA

Josep Tabernero, MD, PhD
Head of the Medical Oncology Department
Vall d’Hebron University Hospital
Barcelona, Spain

Josep Tabernero, MD, PhD
Head of the Medical Oncology Department
Vall d’Hebron University Hospital
Barcelona, Spain

**Agenda**

**Friday, 23 September 2016**

08:00 Welcome & Free Breakfast

09:00 The Science of Cancer Immunotherapy
Moderator: Antoni Ribas, MD, PhD, Rome, Italy

10:00 Opening Keynote: CTLA-4 Blockade Therapy

10:30 Cancer Immunotherapy in the Clinic
Moderator: Prof. Alexander M. Eggermont, MD, PhD, Berlin, Germany

11:00 T-Cell Receptor Recognition of Cancer
Moderator: Dr. Thomas Blankenstein, London, UK

11:30 Morning Break

12:15 Targeting Cancer with Checkpoint Blockade

12:30 Checkpoint Blockade: The New Hope for Cancer Therapeutics

12:35 Adaptive Immunotherapy With Young Tumor-Infiltrating Lymphocytes

13:30 Post-Session Survey

13:35 Lunch Break

15:05 Pre-Session Survey

15:15 Advanced Lung and Head and Neck Cancer: Assessing Single Agent and Combinations in Multiple Lines of Care

15:45 From the CIOMS: Key Emerging Trends To Improve Checkpoint Therapy Efficacy

16:15 Afternoon Break

16:45 Immunotherapeutic Options for Bladder Carcinoma: Efficacy Update and Safety Considerations

17:15 Where Are We and Where Are We Going? Emerging Immunotherapeutic Strategies in Melanoma

17:45 Post-Session Survey and Discussion

18:00 Welcome Reception (Exhibit Hall)

**Saturday, 24 September 2016**

08:00 Welcome & Free Breakfast

08:50 Welcome & Pre-Session Survey

09:00 Immunooncology in the Clinic-I

09:25 What’s Immunogenicity Got To Do With It? Lessons Learned From Gynaecological Cancers

09:55 Tipping the Balance: Strategies for Modulating Tumor-Host Interactions in Hodgkin’s and Other Lymphomas

09:55 Working Together: Rational for Immunotherapy-Containing Combinations in Breast Cancer

10:15 On the Frontier: Immunotherapy for Gastrointestinal Cancers

10:35 Morning Break

12:00 Checkpoints and CAs

12:30 Response to Immune Checkpoint Mechanisms and Clinical Approaches

12:35 Post-Session Survey and Discussion

13:35 Lunch Break

14:35 Pre-Session Survey

15:00 Immunooncology in the Clinic-II

15:25 Understanding Immune Checkpoint Blockade in Melanoma

15:45 How Do Immune Checkpoint Blockade Agents Work?

16:15 Advanced Lung and Head and Neck Cancer: Assessing Single Agent and Combinations in Multiple Lines of Care

16:45 Describing and Discussing the Future of Immune Checkpoint Blockade for Lung Cancer

17:15 Where Are We and Where Are We Going? Emerging Immunotherapeutic Strategies in Melanoma

17:45 Post-Session Survey and Discussion

18:00 Welcome Reception (Exhibit Hall)